Review: Bisphosphonates prevent or delay skeletal events in women with advanced breast cancer and bone metastases

March 2006
ACP Journal Club;Mar/Apr2006, Vol. 144 Issue 2, p39
Academic Journal
This article reports that Bisphosphonates prevent or delay skeletal events in women with advanced breast cancer and bone metastases. 15 randomized controlled trials (RCTs) in women with advanced breast cancer and clinically evident bone metastases, 3 RCTs in women with advanced breast cancer without bone metastases, and 3 RCTs in women with early breast cancer. In category 1, risk for skeletal events was reduced with bisphosphonates and time to the first event was longer in 7 of 10 RCTs, compared with control.


Related Articles

  • Denosumab reduced skeletal events in women with breast cancer and bone metastases.  // Hem/Onc Today;11/25/2008, Vol. 9 Issue 21, p54 

    The article discusses research being done on the effect of denosumab on skeletal-related events in women with breast cancer and bone metastases who had not received intravenous (IV) bisphosphonate. It references a study by Allan Lipton et al, which appeared in the 2008 issue of "Clinical Cancer...

  • Collapsing focal segmental glomerulosclerosis following long-term treatment with oral ibandronate: case report and review of literature. Ning Jia; Cormack, Fionnuala C.; Bin Xie; Zita Shiue; Najafian, Behzad; Gralow, Julie R. // BMC Cancer;Jul2015, Vol. 15 Issue 1, p1 

    Background: Renal toxicity has been reported with bisphosphonates such as pamidronate and zolidronate but not with ibandronate, in the treatment of breast cancer patients with bone metastasis. One of the patterns of bisphosphonate-induced nephrotoxicity is focal segmental glomerulosclerosis...

  • Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art. Clemons, M.; Gelmon, K. A.; Pritchard, K. I.; Paterson, A. H. G. // Current Oncology;Oct2012, Vol. 19 Issue 5, p259 

    Most women with advanced breast cancer will develop bone metastases, which are associated with the development of skeletal-related events (sres) such as pathologic fractures and spinal cord compression. This article reviews the evolving definition and incidence of sres, the pathophysiology of...

  • COMMENTARY: Review: Bisphosphonates prevent or delay skeletal events in women with advance breast cancer and bone metastases. O'Regan, Ruth // ACP Journal Club;Mar/Apr2006, Vol. 144 Issue 2, p39 

    This article presents a study which reveals that Bisphosphonates prevent or delay skeletal events in women with advance breast cancer and bone metastases. Bisphosphonates have a wide spectrum of uses in breast cancer. Researchers reviewed the use of bisphosphonates in 3 specific breast cancer...

  • Recent developments in bisphosphonates for patients with metastatic breast cancer. Gainford, Mary C.; Dranitsaris, George; Clemons, Mark // BMJ: British Medical Journal (International Edition);4/2/2005, Vol. 330 Issue 7494, p769 

    Examines the use of biphosphonates for the treatment of metastatic breast cancer. Incidence of breast cancer in North American women; Design and scope of a literature review of the therapeutic use of biphosphonates for patients with bone metastasis; Discussion of several stages of metastasis in...

  • Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence. Santini, Daniele; Stumbo, Luciano; Spoto, Chiara; D'Onofrio, Loretta; Pantano, Francesco; Iuliani, Michele; fioramonti, Marco; Zoccoli, Alice; Ribelli, Giulia; Virzì, Vladimir; Vincenzi, Bruno; Tonini, Giuseppe // Breast Cancer Research;9/2/2015, Vol. 17 Issue 1, p1 

    Bisphosphonates (BPs) are approved as standard therapy in breast cancer for the treatment of bone metastases, since they were demonstrated to reduce the prevalence of skeletal-related events including fractures and hypercalcemia. In the adjuvant setting, BPs can be given to prevent and treat...

  • Application of Bone Scintigraphy Before Surgery Can Completely Change the Treatment Procedures in Patients with Breast Cancer. Miftari, Rame; Hashani, V.; Bicaj, Xh.; Gjikolli, B.; Fejza, F.; Xhafa, B.; Iberdemaj, R.; Gerqari, I.; Luljeta, A.; Bajqinca, A. // Acta Informatica Medica;2009, Vol. 17 Issue 4, p221 

    Introduction: The aim of this study was to, based on the data collected, determine the right time for the application of bone scintigraphy in patients with breast cancer. Discovery of bone metastasis in their initial stages of development, before the occurrences of clinical signs, can completely...

  • Tamoxifen.  // Reactions Weekly;10/14/2006, Issue 1123, p21 

    The article presents a case study of a 67-year-old woman with breast cancer who developed vasculitis during treatment with tamoxifen for progressive bone metastases. The patient, who had been receiving different adjuvant chemotherapeutic agents for about 7 years, started receiving tamoxifen. The...

  • Treatment of breast cancer with bone metastasis: bisphosphonate treatment — current and future. Kohno, Norio // International Journal of Clinical Oncology;Feb2008, Vol. 13 Issue 1, p18 

    There are a variety of treatments for patients with bone metastases from breast cancer. These include bisphosphonates, antitumor endocrine and cytotoxic systemic therapies, radiotherapy to the metastatic site, radionucleotides, and conservative treatment (analgesics). The optimal combination...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics